TITLE

β-Blocker Use for the Stages of Heart Failure

AUTHOR(S)
KLAPHOLZ, MARC
PUB. DATE
August 2009
SOURCE
Mayo Clinic Proceedings;Aug2009, Vol. 84 Issue 8, p718
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The 2005 American Heart Association/American College of Cardiology heart failure (HF) guidelines contributed to a renewed focus on "at-risk" patients and emphasized HF as a progressive disease. Patient categorization by stages focused attention on customization of therapy to achieve optimal, evidence-based treatments across the HF continuum. Therapy for risk factors that predispose patients to left ventricular dysfunction or other symptoms may help reduce HF development. β-Blockers are valuable for treatment of HF; however, the class is heterogeneous, and proper β-blocker selection for each HF stage is important. β-Blockers have been used routinely to treat patients with stage A HF with hypertension. Recent controversy regarding the detrimental effects that some β-blockers have on metabolic parameters has raised inappropriate concerns about the use of any β-blocker for diabetes. β-Blockade is standard therapy for the patient with stage B HF who has had a myocardial infarction, but few data are available concerning use in asymptomatic patients with left ventricular dysfunction. Additionally, β-blockers are part of the core therapy for stage C HF and selected patients with stage D HF. This review examines the role and use of β-blockers in each HF stage through an evidence-based approach to provide better understanding of their importance in this progressive disease. PubMed searches (1980-2008) Identified large clinical trials that evaluated cardiovascular events and outcomes in any HF stage or hypertension. Search terms were heart failure, hypertension, β-blocker, ACEI, ARB, and calcium channel blocker AND blood pressure coronary artery disease, diabetes, efficacy, left ventricular dysfunction, metabolism, mortality, myocardial infarction, or stroke.
ACCESSION #
43637596

 

Related Articles

  • Guidelines for noncardiac surgery push beta-blockers. Magill-Lewis, Jillene // Drug Topics;3/4/2002, Vol. 146 Issue 5, p26 

    Reports on the team up of the American College of Cardiology and the American Heart Association to create guidelines for the perioperative cardiovascular evaluation for non-cardiac surgery. Benefits of beta-blockers in the prevention of cardiac complications; Indications for beta-blocker...

  • Is the Perioperative Use of β-Blockers Still Recommended? A Critical Review of Recent Controversies. Domanski, Damian; Schwarz, Ernst R. // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2009, Vol. 14 Issue 4, p258 

    The article discusses whether the perioperative use of ß-blockers is still recommended. It discusses the discouraging results of the Perioperative Ischemic Evaluation (POISE) study in May 2008. A report from the American College of Cardiology/American Heart Association (ACC/AHA) which...

  • Abnormal heart rate recovery in patients with heart failure: an important target for exercise training treatment. Dimopoulos, Stavros // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Sep2015, Vol. 15 Issue 9, p735 

    The author reflects on the importance of autonomous nervous system imbalance in patients with chronic heart failures. Topics discussed include clinical recommendations for cardiopulmonary exercise testing (CPET) by the American Heart Association, impact of beta-blocker medications on the results...

  • ACC/AHA Release Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery. Graham, Lisa // American Family Physician;6/15/2008, Vol. 77 Issue 12, p1748 

    The article presents the guidelines on perioperative cardiovascular evaluation for noncardiac surgery that were released by the American College of Cardiology (ACC) and the American Heart Association (AHA). An illustration showing the stepwise approach to such assessment is provided. The article...

  • Perioperative β-Blocker Therapy. Stern, Todd; Cifu, Adam S. // JAMA: Journal of the American Medical Association;6/23/2015, Vol. 313 Issue 24, p2486 

    This article presents information on the "Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery," developed by the American College of Cardiology and American Heart Association. It discusses the guideline's target population, recommendation...

  • Newer Heart Drug Saves Lives. Zipes, Douglas // Medical Update;2003, Vol. 29 Issue 3, p5 

    Presents a study that compared the life span of heart failure patients taking a comprehensive beta-blocker drug and a traditional selective version in several European countries. Therapeutic use of the beta-blocker drug Carvedilol for hypertension; Type of metropolol used in the study;...

  • B -Blocker und ihre Bedeutung fur die Pharmakotherapie kardiovaskularer Erkrankungen im Vergleich. Wehling, Martin // Drug Research / Arzneimittel-Forschung;Feb2002, Vol. 52 Issue 2, p73 

    Comparing a -Blockers and their Relev-ance in the Pharmacotherapy of Cardio-vascular Diseases a -Blockers have regained interest in the treatment of cardiovascular diseases after a period of decreasing importance due to the introduction of other cardio-vascular treatment principles. a...

  • ACC/AHA Guideline Update for the Management of ST-Segment Elevation Myocardial Infarction. CAMPBELL-SCHERER, DENISE L.; GREEN, LEE A. // American Family Physician;6/15/2009, Vol. 79 Issue 12, p1080 

    The American College of Cardiology and American Heart Association, in collaboration with the Canadian Cardiovascular Society, have issued an update of the 2004 guideline for the management of patients with ST-segment elevation myocardial infarction. The American Academy of Family Physicians...

  • What the new guidelines offer for preoperative risk reduction. Eagle, Kim A.; Smetana, Gerald W.; Pelus, Sandra // Patient Care;Oct2006, Vol. 40 Issue 10, p18 

    The article provides information on the guidelines issued by the American College of Cardiology and the American Heart Association on the use of beta-blockers in preoperative cardiac risk reduction. It dosage and duration of taking beta-blockers. It suggests approached to patients who are at...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics